Funding for this research was provided by:
Pfizer (Not applicable)
Text and Data Mining valid from 2020-01-03
Received: 27 July 2019
Accepted: 13 December 2019
First Online: 3 January 2020
Ethics approval and consent to participate
: The EMBARK study was conducted in accordance with International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki. Institutional review board approval and informed consent from all participants were obtained prior to study initiation.
: Not applicable.
: MD has received consulting fees from AbbVie, Celgene, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB. DvdH has received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB, and is the director of Imaging Rheumatology BV. W-CT has received consulting fees from AbbVie, Pfizer, and Roche. DS has no conflicts to declare. RP, LM, and HJ were employees of Pfizer at the time of the study and have company stock options/bond holdings. BV and MT are employees of Pfizer and have company stock options/bond holdings.